| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $5,040,000 | 2 | 100 |
Sells | $0 | 0 | 0 |
| Foresite Capital Management V, LLC | 10 percent owner | 1 | $2.52M | 0 | $0 | $2.52M |
| Tananbaum James B. | 1 | $2.52M | 0 | $0 | $2.52M |
Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its products include Molecule: LTG-001, Molecule: LTG-32, Molecule: LTG-001 IV and Molecule: LTG-418. The company was founded on November 20, 2018 and is headquartered in Thousand Oak, CA.
Over the last 12 months, insiders at Latigo Biotherapeutics Inc. have bought $5.04M and sold $0 worth of Latigo Biotherapeutics Inc. stock.
On average, over the past 5 years, insiders at Latigo Biotherapeutics Inc. have bought $5.04M and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Foresite Capital Management V, LLC (10 percent owner) — $2.52M. Tananbaum James B. () — $2.52M.
The last purchase of 140,000 shares for transaction amount of $2.52M was made by Tananbaum James B. () on 2026‑08‑10.
| 2026-08-10 | Tananbaum James B. | 140,000 0.2257% | $18.00 | $2.52M | +1.89% | |||
| 2026-08-10 | Foresite Capital Management V, LLC | 10 percent owner | 140,000 0.2257% | $18.00 | $2.52M | +1.89% |
| Increased Positions | 0 | 0% | 0 | 0% |
| Decreased Positions | 0 | 0% | 0 | 0% |
| New Positions | 0 | New | 0 | New |
| Sold Out Positions | 0 | Sold Out | 0 | Sold Out |
| Total Postitions | 0 | 0% | 0 | 0% |